# What's new on the global vaccine policy agenda?

Joachim Hombach, WHO

ARVAC vaccinology refresher





## World Health Organization


## IVB report: 50 years EPI.....

## Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization

Andrew J Shattock, Helen C Johnson, So Yoon Sim, Austin Carter, Philipp Lambach, Raymond C W Hutubessy, Kimberly M Thompson, Kamran Badizadegan, Brian Lambert, Matthew J Ferrari, Mark Jit, Han Fu, Sheetal P Silal, Rachel A Hounsell, Richard G White, Jonathan F Mosser, Katy A M Gaythorpe, Caroline L Trotter, Ann Lindstrand, Katherine L O'Brien, Naor Bar-Zeev


### EPI@50 impact modeling analysis published in the Lancet:

- Since 1974, vaccination has averted over 154 million deaths and 10.2 billion years of full health were gained (disabilityadjusted life years averted)
- Measles vaccination accounts for 60% (94 million deaths averted)
- Vaccination has accounted for 40% of the reduction in infant deaths globally, and over 50% in the African region.
- In 2024, a child younger than 10 years is 40% more likely to survive to their next birthday than if no vaccinations had occurred since 1974.
- Benefits of vaccination continue up to and beyond 50 years of age



#### https://doi.org/10.1016/S0140-6736(24)00850-X


## The #vaccine preventable diseases has massively expanded From 7 VPDs in 1974...... to >13 in 2024



## And will continue to expand in the short and medium term....

**Respiratory Syncytial Virus** Chikungunya

#### **Recently Licensed**



## Policy updates released and in preparation/planning

Policy positions released

- Multivalent ACWYX Conj. Vaccine in the meningitis belt, Jan. 2024
- Mumps, March 2024
- Dengue, May 2024
- Malaria, May 2024
- C19 update, May 2024 SAGE meeting report

- phase

#### 2025 and beyond

#### Policy positions under review or in planning

Ebola, June 2024

Mpox and smallpox, Aug. 2024

RSV, end of 2024

Global MMCV and Men B, end of 2024/beginning 2025

Varicella Zoster, end of 2024

Typhoid, end of 2025

Pneumococcus, end of 2025

HPV, end of 2025

Chikungunya, end of 2025

Yellow Fever, 2026?

Japanese Encephalitis, 2026?

## Major issues ahead

#### Increasing need for country prioritization Life-course vaccination options becoming a reality

HPV, MCV2, malaria, dengue, typhoid, pneumococcus adult, influenza, zoster, RSV adult, etc.

- - Variable burden of disease and cost effectiveness between countries and within countries
  - Limited fiscal space and absorption capacities of countries
  - Schedule, programme, acceptability and logistic considerations
- NEED for countries to assess different options on objective criteria:

  - Weigh between possible new vaccines introductions
  - Increase coverage of existing vaccines
  - Focus on particular risk groups

In light of :

Ever increasing vaccine portfolio